A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)

Part of paid clinical trials in Hoover, Alabama.

Sponsor
Incyte Corporation
Study ID
NCT06113445
Phase
PHASE3
Status
Active Not Recruiting

Conditions

  • NonSegmental Vitiligo

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Povorcitinib — DRUG
    Oral, Tablet
  • Placebo — DRUG
    Oral, Tablet

Study Details

This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.

Key Dates

Start date
Nov 29, 2023
Status verified
Mar 2026
Primary completion
Feb 24, 2026
Completion
Feb 24, 2027

Study Design

Enrollment
467 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Experimental: Povorcitinib Dose A
    Participants will receive Povorcitinib Dose A for 52 weeks, followed by Povorcitinib Dose A for 52 weeks.
  • Placebo Comparator: Placebo
    Participants will receive Placebo for 52 weeks, followed by Povorcitinib Dose A for 52 weeks.

Primary Outcome Measure

Proportion of Participants Achieving a ≥ 75% Improvement From Baseline in the Facial Vitiligo Area Scoring Index (F-VASI75) [ Time Frame: Week 52 ]

Locations (34)

FacilityCityStateZIPSite coordinators
Cahaba DermatologyHooverAlabama35244-
University of California IrvineIrvineCalifornia92697-
Clinical Science Institute Clinical Research Specialists IncSanta MonicaCalifornia90404-
Cura Clinical ResearchSherman OaksCalifornia91403-
Sutter Health Palo Alto Medical Foundation Pamf Sunnyvale CenterSunnyvaleCalifornia94086-
Renaissance ResearchCape CoralFlorida33991-
Encore Medical Research, LlcHollywoodFlorida33021-
Savin Medical Group, RcMiamiFlorida33156-
Skin Research of South Florida, LlcMiamiFlorida33173-
San Marcus Research Clinic Inc.Miami LakesFlorida33014-
Forcare Clinical ResearchTampaFlorida33613-
Olympian Clinical ResearchTampaFlorida33609-
Cleaver Medical GroupCummingGeorgia30040-
Dermatology and Surgery Specialists of North AtlantaMariettaGeorgia30068-
Pivotal Research SolutionsStonecrestGeorgia30038-
Options Research Group, LlcKokomoIndiana46901-
Allcutis Research, LlcBeverlyMassachusetts01915-
Metro Boston Clinical PartnersBrightonMassachusetts02135-3511-
Great Lakes Research Group IncBay CityMichigan48706-
Wayne State University Physician Group DermatologyDearbornMichigan48124-
Revival Research Institute, Llc DermatologyTroyMichigan48084-
Medisearch Clinical TrialsSaint JosephMissouri64506-
Jdr Dermatology ResearchLas VegasNevada89148-
Empire DermatologyEast SyracuseNew York13057-
Sadick Dermatology Sadick Research GroupNew YorkNew York10075-
Derm Research Center of New York IncStony BrookNew York11790-
Dermatology Associates of Plymouth MeetingPlymouth MeetingPennsylvania19462-
International Clinical Research Tennessee LlcMurfreesboroTennessee37130-
University of Texas Physicians - Bellaire StationBellaireTexas77401-
Center For Clinical StudiesHoustonTexas77004-
Progressive Clinical ResearchSan AntonioTexas78213-
Jordan Valley Dermatology CenterWest JordanUtah84088-
Clinical Research Partners Llc Crp Richmond Forest Avenue Office Building LocationRichmondVirginia23226-
Dermatology Specialists of SpokaneSpokaneWashington99202-

Find similar trials in Hoover, AL

By research site
Cahaba Dermatology· Hoover, ALUniversity of California Irvine· Irvine, CAClinical Science Institute Clinical Research Specialists Inc· Santa Monica, CACura Clinical Research· Sherman Oaks, CASutter Health Palo Alto Medical Foundation Pamf Sunnyvale Center· Sunnyvale, CARenaissance Research· Cape Coral, FL

Related Studies